PHRMASI
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
Phaarmasia Says Maneesh Ramakant Sapte Has Resigned As Managing Director
March 31 (Reuters) - Phaarmasia Ltd PHRM.BO:
MANEESH RAMAKANT SAPTE HAS RESIGNED AS MANAGING DIRECTOR
Source text for Eikon: ID:nBSE83jqhK
Further company coverage: PHRM.BO
(([email protected];))
March 31 (Reuters) - Phaarmasia Ltd PHRM.BO:
MANEESH RAMAKANT SAPTE HAS RESIGNED AS MANAGING DIRECTOR
Source text for Eikon: ID:nBSE83jqhK
Further company coverage: PHRM.BO
(([email protected];))
Events:
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Phaarmasia do?
Phaarmasia Ltd specializes in manufacturing pharmaceutical formulations like amexine, angicare, flamfort, and their therapeutic nasal spray, nasorel PR, falls under the antihistamine and sympathomimetic category.
Who are the competitors of Phaarmasia?
Phaarmasia major competitors are Chemo Pharma Labs, Hamps Bio, Norris Medicines, Desh Rakshak Aushdh, Link Pharma Chem, Emmessar Biotech&Nut, Colinz Laboratories. Market Cap of Phaarmasia is ₹19 Crs. While the median market cap of its peers are ₹17 Crs.
Is Phaarmasia financially stable compared to its competitors?
Phaarmasia seems to be less financially stable compared to its competitors. Altman Z score of Phaarmasia is 1.37 and is ranked 6 out of its 8 competitors.
Does Phaarmasia pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Phaarmasia latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Phaarmasia allocated its funds?
Companies resources are allocated to majorly unproductive assets like Inventory
How strong is Phaarmasia balance sheet?
Phaarmasia balance sheet is weak and might have solvency issues
Is the profitablity of Phaarmasia improving?
The profit is oscillating. The profit of Phaarmasia is -₹1.59 Crs for TTM, -₹0.52 Crs for Mar 2024 and -₹1.26 Crs for Mar 2023.
Is the debt of Phaarmasia increasing or decreasing?
Yes, The net debt of Phaarmasia is increasing. Latest net debt of Phaarmasia is -₹0.36 Crs as of Mar-25. This is greater than Mar-24 when it was -₹1.27 Crs.
Is Phaarmasia stock expensive?
Phaarmasia is not expensive. Latest PE of Phaarmasia is -12.06, while 3 year average PE is 11.45. Also latest EV/EBITDA of Phaarmasia is 0.0 while 3yr average is 3.38.
Has the share price of Phaarmasia grown faster than its competition?
Phaarmasia has given lower returns compared to its competitors. Phaarmasia has grown at ~-4.03% over the last 7yrs while peers have grown at a median rate of 11.0%
Is the promoter bullish about Phaarmasia?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Phaarmasia is 73.51% and last quarter promoter holding is 73.51%.
Are mutual funds buying/selling Phaarmasia?
There is Insufficient data to gauge this.